HER2 equivocal status in early breast cancer is not associated with higher risk of recurrence

Carmen Criscitiello; Vincenzo Bagnardi; Giuseppe Viale; Davide Disalvatore; Nicole Rotmensz; Angela Esposito; Aron Goldhirsch; Giuseppe Curigliano

HER2 equivocal status in early breast cancer is not associated with higher risk of recurrence

Carmen Criscitiello, Vincenzo Bagnardi, Giuseppe Viale, Davide Disalvatore, Nicole Rotmensz, Angela Esposito, Aron Goldhirsch, Giuseppe Curigliano

Istituto Europeo di Oncologia

Research output: Contribution to journal › Article › peer-review

Abstract

Aim: The primary aim of the study was to assess the association between risk of recurrence and HER2 equivocal gene status through immunohistochemistry in patients with early breast cancer. Patients and Methods: We retrospectively analyzed clinical and pathological data of 455 consecutive patients with early breast cancer (BC) who were HER2+ and had a HER2/CEP17 ratio <2.0, who underwent surgery at the European Institute of Oncology after 2007. The role of HER2/CEP17 ratio on recurrencefree survival was assessed with univariate and multivariate Cox regression models. Results: We found no significant association between risk of recurrence and HER2 equivocal testing in patients with early breast cancer. In subgroup analysis, a significant interaction between HER2/CEP17 ratio and nodal involvement was observed (p=0.02). Conclusion: Patients with HER2 equivocal status have no significantly higher risk of recurrence.

Original language	English
Pages (from-to)	3537-3540
Number of pages	4
Journal	Anticancer Research
Volume	36
Issue number	7
Publication status	Published - 2016

Keywords

Breast cancer
Equivocal HER2 status
HER2 amplification
Heterogeneity

ASJC Scopus subject areas

Oncology
Cancer Research

Cite this

@article{494bacaf379c4bd9b8c4ad01523555e3,

title = "HER2 equivocal status in early breast cancer is not associated with higher risk of recurrence",

abstract = "Aim: The primary aim of the study was to assess the association between risk of recurrence and HER2 equivocal gene status through immunohistochemistry in patients with early breast cancer. Patients and Methods: We retrospectively analyzed clinical and pathological data of 455 consecutive patients with early breast cancer (BC) who were HER2+ and had a HER2/CEP17 ratio <2.0, who underwent surgery at the European Institute of Oncology after 2007. The role of HER2/CEP17 ratio on recurrencefree survival was assessed with univariate and multivariate Cox regression models. Results: We found no significant association between risk of recurrence and HER2 equivocal testing in patients with early breast cancer. In subgroup analysis, a significant interaction between HER2/CEP17 ratio and nodal involvement was observed (p=0.02). Conclusion: Patients with HER2 equivocal status have no significantly higher risk of recurrence.",

keywords = "Breast cancer, Equivocal HER2 status, HER2 amplification, Heterogeneity",

author = "Carmen Criscitiello and Vincenzo Bagnardi and Giuseppe Viale and Davide Disalvatore and Nicole Rotmensz and Angela Esposito and Aron Goldhirsch and Giuseppe Curigliano",

year = "2016",

language = "English",

volume = "36",

pages = "3537--3540",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "7",

}

TY - JOUR

T1 - HER2 equivocal status in early breast cancer is not associated with higher risk of recurrence

AU - Criscitiello, Carmen

AU - Bagnardi, Vincenzo

AU - Viale, Giuseppe

AU - Disalvatore, Davide

AU - Rotmensz, Nicole

AU - Esposito, Angela

AU - Goldhirsch, Aron

AU - Curigliano, Giuseppe

PY - 2016

Y1 - 2016

N2 - Aim: The primary aim of the study was to assess the association between risk of recurrence and HER2 equivocal gene status through immunohistochemistry in patients with early breast cancer. Patients and Methods: We retrospectively analyzed clinical and pathological data of 455 consecutive patients with early breast cancer (BC) who were HER2+ and had a HER2/CEP17 ratio <2.0, who underwent surgery at the European Institute of Oncology after 2007. The role of HER2/CEP17 ratio on recurrencefree survival was assessed with univariate and multivariate Cox regression models. Results: We found no significant association between risk of recurrence and HER2 equivocal testing in patients with early breast cancer. In subgroup analysis, a significant interaction between HER2/CEP17 ratio and nodal involvement was observed (p=0.02). Conclusion: Patients with HER2 equivocal status have no significantly higher risk of recurrence.

AB - Aim: The primary aim of the study was to assess the association between risk of recurrence and HER2 equivocal gene status through immunohistochemistry in patients with early breast cancer. Patients and Methods: We retrospectively analyzed clinical and pathological data of 455 consecutive patients with early breast cancer (BC) who were HER2+ and had a HER2/CEP17 ratio <2.0, who underwent surgery at the European Institute of Oncology after 2007. The role of HER2/CEP17 ratio on recurrencefree survival was assessed with univariate and multivariate Cox regression models. Results: We found no significant association between risk of recurrence and HER2 equivocal testing in patients with early breast cancer. In subgroup analysis, a significant interaction between HER2/CEP17 ratio and nodal involvement was observed (p=0.02). Conclusion: Patients with HER2 equivocal status have no significantly higher risk of recurrence.

KW - Breast cancer

KW - Equivocal HER2 status

KW - HER2 amplification

KW - Heterogeneity

UR - http://www.scopus.com/inward/record.url?scp=84992116230&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992116230&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84992116230

VL - 36

SP - 3537

EP - 3540

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 7

ER -

HER2 equivocal status in early breast cancer is not associated with higher risk of recurrence

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this